A5079541227- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Cancer, Lipids, and Metabolism
- Cancer Mechanisms and Therapy
- Liver physiology and pathology
- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Thyroid Cancer Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Drug-Induced Hepatotoxicity and Protection
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Ferroptosis and cancer prognosis
- Ovarian cancer diagnosis and treatment
- Economic and Financial Impacts of Cancer
- Advanced Breast Cancer Therapies
- Pharmacogenetics and Drug Metabolism
- Gastric Cancer Management and Outcomes
Bayer (Switzerland)
2020-2024
Bayer (United States)
2021
Background: Sorafenib and lenvatinib are multikinase inhibitors (MKIs) approved for patients with radioactive iodine-refractory (RAI-R) differentiated thyroid cancer (DTC). There is no consensus on when to initiate MKI treatment. The objective of this study was evaluate time symptomatic progression (TTSP) in RAI-R DTC whom the decision treat an made at entry. Methods: International, prospective, open-label, noninterventional cohort (NCT02303444). Eligible had asymptomatic progressive DTC, ≥1...
433 Background: Regorafenib improved OS versus placebo in patients with uHCC who progressed on prior sorafenib the RESORCE trial (Bruix J, 2017). An interim analysis of observational REFINE study supported safety and effectiveness regorafenib real-world clinical practice (Lim HY, 2021). Here we present an exploratory by treatment. Methods: is a multicenter that enrolled for whom decision to treat made treating physician enrollment according local health authority approved label. The primary...
Real-world (RW) evidence is needed to evaluate atezolizumab plus bevacizumab (atezo + bev) utilization for hepatocellular carcinoma (HCC) in clinical practice. This retrospective cohort study used administrative claims databases treatment patterns individuals with HCC ≥18 years of age who were initiated on atezo bev between June 2020 and 2022. The endpoints this the proportion discontinued received subsequent systemic therapies, time discontinuation (TTD), next treatment. Overall, 825...
The tyrosine kinase inhibitors regorafenib and cabozantinib remain the mainstay in second-line treatment of advanced hepatocellular carcinoma (HCC). There is currently no clear evidence superiority efficacy or safety to guide choice between two treatments.We conducted an anchored matching-adjusted indirect comparison using individual patient data from RESORCE trial published aggregate CELESTIAL cabozantinib. Second-line HCC patients with prior sorafenib exposure ≥3 months were included...
542 Background: Regorafenib significantly improved overall survival (OS) versus placebo in patients (pts) with uHCC who progressed on prior sorafenib therapy the phase 3 RESORCE trial. The multicenter, international REFINE trial was designed to evaluate safety and effectiveness of regorafenib real-world setting. Methods: This prospective, observational aims recruit 1000 pts for whom a decision treat has been made by treating physician enrollment according local health authority approved...
Objectives Regorafenib improved overall survival in patients with metastatic colorectal cancer (mCRC) refractory to standard therapies two randomised, phase III trials, but has not been evaluated Turkey. REGARD the safety and efficacy of regorafenib Turkish treatment-refractory mCRC. Design Open-label, single-arm, IIIb study conducted between July 2013 April 2015. Setting 11 tertiary centres Participants Eligible were adults mCRC who had disease progression within 3 months after receiving...
452 Background: Pts with HCC and compromised liver function are typically excluded from clinical trials. The REFINE real-world study (NCT03289273) assessed a more varied pt population treated regorafenib than the phase 3 RESORCE trial. 1 Median overall survival (OS) in was 13.2 months treatment-emergent adverse events (TEAEs) were consistent RESORCE. We present subgroup analysis of outcomes pts CP-B function. Methods: is an international, prospective observational uHCC for whom decision to...
Introduction: In the phase 3 RESORCE trial, regorafenib prolonged overall survival (OS) in patients with unresectable hepatocellular carcinoma (uHCC) whose disease progressed on prior sorafenib. The prospective, observational REFINE study aimed to evaluate safety and effectiveness of a broader population real-world clinical practice, including Eastern Cooperative Oncology Group performance status (ECOG PS) ≥2, Child–Pugh B liver status, sorafenib-intolerance. Methods: This international,...
518 Background: Final results from the real-world REFINE study confirmed safety and effectiveness of regorafenib (REG) in a broad population patients (pts) with uHCC that was consistent RESORCE, which REG prolonged overall survival (OS) vs placebo pts who progressed on prior sorafenib. Here we evaluate baseline characteristics outcomes according to initial dose. Methods: (NCT03289273), an international, prospective, multicenter study, enrolled for whom decision treat made by treating...
e16680 Background: REG is approved for the treatment of pts with HCC who previously received SOR, based on results phase 3 RESORCE trial. The REFINE study was designed to evaluate safety and effectiveness in real-world practice. Methods: This prospective, observational aims recruit 1000 unresectable whom a decision treat made by treating physician prior enrollment according local health authority label. primary endpoint incidence treatment-emergent adverse events (TEAEs) dose modifications...
e16114 Background: In the observational REFINE study of regorafenib (NCT03289273) in pts with uHCC, treatment-emergent adverse events (TEAEs) were consistent those reported global, phase 3 RESORCE trial (YJ Kim, ILCA 2022). Median overall survival (OS) global cohort was 13.2 months; here, we present final analysis US pt cohort. Methods: an international, prospective, multicenter that enrolled uHCC for whom a decision to treat made by treating physician prior enrollment, according local...
529 Background: Regorafenib is the only licensed second-line therapy available for patients with advanced hepatocellular carcinoma (HCC) that progress on first-line sorafenib in UK. We evaluated lifetime cost-effectiveness of a sequence treatment followed by regorafenib (SOR-REG) compared single-line therapies which there no clear sequencing options available, including atezolizumab plus bevacizumab (ATEZO+BEV), has become standard care treatment, as well lenvatinib (LEN), best supportive...
e16188 Background: REG and CAB, two therapies for second-line (2L) advanced HCC, have been evaluated vs. placebo (PBO) in randomized phase III trials, RESORCE (NCT01774344) CELESTIAL (NCT01908426), respectively. In the absence of head-to-head studies, indirect treatment comparison (ITC) is needed to compare efficacy safety CAB. Anchored MAIC an ITC method adjusting cross-trial heterogeneity using PBO as common comparator or anchor. Methods: Patient-level data from were available match...